Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol

No abstract is available for this paper.

• Publication year

  1992

• Venue

  Clinical pharmacology and therapy

• Publication date

  1992-01-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1038/clpt.1992.3PMID 1732074
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhibition of methylprednisolone elimination in the presence of erythromycin therapy.

  1999cited by this paper
• Molecular genetics of the P-450 superfamily.

  1990cited by this paper
• Identification of the rabbit and human cytochromes P-450IIIA as the major enzymes involved in the N-demethylation of diltiazem.

  1990cited by this paper
• Characterization of mRNA species related to human liver cytochrome P-450 nifedipine oxidase and the regulation of catalytic activity.

  1989cited by this paper
• Characterization of a cDNA encoding a new member of the glucocorticoid-responsive cytochromes P450 in human liver.

  1989cited by this paper
• Identification of a polymorphically expressed member of the human cytochrome P-450III family.

  1989cited by this paper
• Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine.

  1989cited by this paper
• Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients.

  1989cited by this paper
• Corticosterone is converted to 6 beta-hydroxycorticosterone in rat: effects of the metabolite on urinary electrolyte excretion.

  1988cited by this paper
• Identification of a cytochrome P-450 in human fetal liver related to glucocorticoid-inducible cytochrome P-450HLp in the adult.

  1988cited by this paper
• Obesity as a risk factor for drug-induced organ injury. VI. Increased hepatic P450 concentration and microsomal ethanol oxidizing activity in the obese overfed rat.

  1988cited by this paper
• The immunocytochemical localisation and distribution of cytochrome P-450 in normal human hepatic and extrahepatic tissues with a monoclonal antibody to human cytochrome P-450.

  1988cited by this paper
• Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6 beta-hydroxylase cytochrome P-450 enzyme.

  1988cited by this paper
• Significance of cytochrome P-450 (P-450 HFLa) of human fetal livers in the steroid and drug oxidations.

  1987cited by this paper
• Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism.

  1986cited by this paper
• Complete cDNA sequence of a cytochrome P-450 inducible by glucocorticoids in human liver.

  1986cited by this paper
• Isolation and sequence determination of a cDNA clone related to human cytochrome P-450 nifedipine oxidase.

  1986cited by this paper
• Regulation of rat hepatic cytochrome P-450: age-dependent expression, hormonal imprinting, and xenobiotic inducibility of sex-specific isoenzymes.

  1985cited by this paper
• Identification of an inducible form of cytochrome P-450 in human liver.

  1985cited by this paper
• A corticosterone metabolite produced by A6 (toad kidney) cells in culture: identification and effects on Na+ transport.

  1985cited by this paper
• Regioselectivity and stereoselectivity of androgen hydroxylations catalyzed by cytochrome P-450 isozymes purified from phenobarbital-induced rat liver.

  1983cited by this paper
• 6β‐Hydroxycortisol in random urine samples as an indicator of enzyme induction

  1983cited by this paper
• 6 beta-hydroxycortisol in random urine samples as an indicator of enzyme induction.

  1983cited by this paper
• Testosterone metabolism by cytochrome P-450 isozymes RLM3 and RLM5 and by microsomes. Metabolite identification.

  1983cited by this paper
• Intersubject and dose-related variability after intravenous administration of erythromycin.

  1980cited by this paper
• Quantitative determination by HPLC of urinary 6β-hydroxycortisol, an indicator of enzyme induction by rifampicin and antiepileptic drugs

  1979cited by this paper
• Radioimmunoassay of 6beta-hydroxycortisol in human plasma and urine.

  1977cited by this paper
• Urinary excretion of 6 beta-hydroxycortisol in states of altered thyroid function.

  1969cited by this paper
• Urinary Excretion of 6β-Hydroxycortisol in States of Altered Thyroid Function

  1969cited by this paper

• Deconvoluting Gut Versus Liver Cytochrome P450 3A4 Function: Drug Probes, Biomarkers, and Tissue Biopsy

  2026cites this paper
• Prediction of CYP3A-mediated drug-drug interactions using endogenous biomarkers 6β-hydroxycortisol and cortisol.

  2025cites this paper
• Cytochrome P450 3A4 activity and genetic variants as predictors of liver failure in patients with obstructive jaundice.

  2023cites this paper
• Pharmacokinetics of obese adults: Not only an increase in weight.

  2023cites this paper
• In vitro effects of quinine on the antibacterial activity of erythromycin against bacteria of clinical relevance

  2021cites this paper
• Identification of Erythromycin and Clarithromycin Metabolites Formed in Chicken Liver Microsomes Using Liquid Chromatography–High-Resolution Mass Spectrometry

  2021cites this paper
• Impact of the Selective Orexin‐1 Receptor Antagonist ACT‐539313 on the Pharmacokinetics of the CYP3A Probe Drug Midazolam in Healthy Male Subjects

  2020cites this paper
• Verification of P-Glycoprotein Function at the Dermal Barrier in Diffusion Cells and Dynamic “Skin-On-A-Chip” Microfluidic Device

  2020cites this paper
• Everolimus Exposure and Early Metabolic Response as Predictors of Treatment Outcomes in Breast Cancer Patients Treated with Everolimus and Exemestane

  2018cites this paper
• Investigation Into Roseburia Intesinalis For Optimal Growth And Survivability Conditions For Potential Probiotic Use

  2017cites this paper
• In vivo Phenotyping Methods: Cytochrome P450 Probes with Emphasis on the Cocktail Approach.

  2017cites this paper
• Sex differences in responsiveness to the prescription opioid oxycodone in mice.

  2016cites this paper
• Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK

  2015cites this paper
• The impact of obesity on the pharmacology of medications used for cardiovascular risk factor control.

  2015cites this paper
• CYP3A5 polymorphism, amlodipine and hypertension

  2014cites this paper
• Validated Bioanalytical Method Development for the Determination of Alosetron in Human K2edta Plasma by Using LC-MS/MS

  2014cites this paper
• Genotype-phenotype variability in human CYP3A locus in Nepalese people residing in Bangladesh.

  2013cites this paper
• Pharmacologie de la morphine chez les sujets obèses avant et après chirurgie de l'obésité

  2013cites this paper
• The influence of morbid obesity on the pharmacokinetics and pharmacodynamics of drugs in adolescents and adults : focus on propofol and nadroparin.

  2013cites this paper
• The influence of morbid obesity on the pharmacokinetics and pharmacodynamics of drugs in adolescents and adults : focus on propofol and nadroparin

  2013cites this paper
• Association between urinary 6β-hydroxycortisol/cortisol ratio and CYP3A5 genotypes in a normotensive population

  2012cites this paper
• Impact of Obesity on Drug Metabolism and Elimination in Adults and Children

  2012cites this paper
• Clinical Consequences of Altered Drug Disposition in Obesity

  2012cites this paper
• Influence of Panax ginseng on Cytochrome P450 (CYP)3A and P‐glycoprotein (P‐gp) Activity in Healthy Participants

  2012cites this paper
• Suszeptibilitätsmarker [Biomonitoring Methods in German language, 2004]

  2012cites this paper
• "In-vivo" phenotyping of CYP3A using midazolam as probe drug : development of novel approaches based on highly sensitive LC-MS/MS methods

  2011cites this paper
• Tacrolimus pharmacokinetics in Hispanic children after kidney transplantation.

  2011cites this paper
• Drug disposition in obesity and protein–energy malnutrition

  2010cites this paper
• Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment.

  2009cites this paper
• Evaluation of CYP3A activity in humans using three different parameters based on endogenous cortisol metabolism

  2009cites this paper
• Influence of Overweight and Obesity on Medication

  2009cites this paper
• Endogenous cortisol 6 beta-hydroxylation clearance is not an accurate probe for overall cytochrome P450 3A phenotyping in humans.

  2009cites this paper
• Association of CYP3A5 Polymorphisms with Hypertension and Antihypertensive Response to Verapamil

  2007cites this paper
• Increased Intrathecal Chemokine Receptor CCR2 Expression in Multiple Sclerosis.

  2007cites this paper
• Sex-dependent genetic markers of CYP3A4 expression and activity in human liver microsomes.

  2007cites this paper
• Study of the Urinary Ratio of 6 β-Hydroxycortisol/Cortisol as a Biomarker of CYP3A4 Activity in Egyptian Patients with Chronic Liver Diseases

  2006cites this paper
• Poor correlation between 6beta-hydroxycortisol:cortisol molar ratios and midazolam clearance as measure of hepatic CYP3A activity.

  2006cites this paper
• Lack of In Vivo Correlation Between Indinavir and Saquinavir Exposure and Cytochrome P450 3A Phenotype as Assessed with Oral Midazolam as a Phenotype Probe

  2006cites this paper
• A warfarin‐dosing model in Asians that uses single‐nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9

  2006cites this paper
• Design and Data Analysis in Drug Interaction Studies

  2005cites this paper
• Association Between the CYP 3 A 5 Genotype and Blood Pressure

  2005cites this paper
• Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol.

  2005cites this paper
• Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests.

  2005cites this paper
• Association Between the CYP3A5 Genotype and Blood Pressure

  2005cites this paper
• Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs

  2005cites this paper
• Alprazolam as a probe for CYP3A using a single blood sample: pharmacokinetics of parent drug, and of α- and 4-hydroxy metabolites in healthy subjects

  2005cites this paper
• [(13)C-breath tests for the assessment of liver function].

  2004cites this paper
• In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam

  2004cites this paper
• 13C-basierte Atemtests in der Leberfunktionsdiagnostik

  2004cites this paper
• Interaction of the Glucocorticoid Receptor and the Chicken Ovalbumin Upstream Promoter‐Transcription Factor II (COUP‐TFII): Implications for the Actions of Glucocorticoids on Glucose, Lipoprotein, and Xenobiotic Metabolism

  2004cites this paper
• Exposure-response relationships and drug interactions of sirolimus

  2004cites this paper
• Cytochrome P450 3A and their regulation

  2004cites this paper
• Simultaneous determination of dexamethasone and 6 beta-hydroxydexamethasone in urine using solid-phase extraction and liquid chromatography: applications to in vivo measurement of cytochrome P450 3A4 activity.

  2004cites this paper
• Genetics of the variable expression of CYP3A in humans.

  2004cites this paper
• Effect of concomitant administration of cimetidine and ranitidine on the pharmacokinetics and electrocardiographic effects of terfenadine

  2004cites this paper
• Alosetron repeat dose pharmacokinetics, effects on enzyme activities, and influence of demographic factors

  2004cites this paper
• Influence of Obesity on Drug Disposition and Effect

  2004cites this paper
• Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of ethosuximide by human hepatic microsomal enzymes

  2003cites this paper
• Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals.

  2003cites this paper
• Quinine 3-hydroxylation as a biomarker reaction for the activity of CYP3A4 in man

  2003cites this paper
• How useful is the ‘cocktail approach’ for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo?

  2003cites this paper
• Relationship between CYP3A activity and breast cancer susceptibility in Chinese Han women

  2003cites this paper
• Urinary 6β-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals

  2003cites this paper
• Evidence for the validity of cortisol 6 beta-hydroxylation clearance as a new index for in vivo cytochrome P450 3A phenotyping in humans.

  2003cites this paper
• Cytochrome P4503A4 metabolic activity, methadone blood concentrations, and methadone doses.

  2003cites this paper
• CYP Gene Induction by Xenobiotics and Drugs

  2003cites this paper
• Short Communication EVIDENCE FOR THE VALIDITY OF CORTISOL 6-HYDROXYLATION CLEARANCE AS A NEW INDEX FOR IN VIVO CYTOCHROME P450 3A PHENOTYPING IN HUMANS

  2003cites this paper
• Approaches to Studying the Development of Drug Metabolism in Children

  2002cites this paper
• Identification of the human P450 enzymes involved in the in vitro metabolism of the synthetic steroidal hormones Org 4060 and Org 30659

  2002cites this paper
• Interindividual Variability of the Clinical Pharmacokinetics of Methadone

  2002cites this paper
• Rat and human liver cytochrome P-450 isoform metabolism of ecteinascidin 743 does not predict gender-dependent toxicity in humans.

  2002cites this paper
• Midazolam and cortisol metabolism before and after CYP3A induction in humans.

  2001cites this paper
• Race but Not Age Affects Erythromycin Breath Test Results in Older Hypertensive Men

  2001cites this paper
• In Vivo Probes for Studying Induction and Inhibition of Cytochrome P450 Enzymes in Humans

  2001cites this paper
• Effects of grapefruit juice on the pharmacokinetics of selected CYP3A4 substrate drugs

  2001cites this paper
• Assessment of drug-drug interactions: concepts and approaches

  2001cites this paper
• Developmental aspects of midazolam metabolism

  2001cites this paper
• Use of the erythromycin breath test for in vivo assessments of cytochrome P4503A activity and dosage individualization

  2001cites this paper
• New strategies for cancer therapy in the 21st century

  2001cites this paper
• Chapter Cytochrome P 450 3 A . Ontogeny and drug disposition 2

  2001cites this paper
• Problems and perspectives of phenotyping for drug-metabolizing enzymes in man.

  2000cites this paper
• Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol.

  2000cites this paper
• Correlation B etween D ocetaxel C learance a nd E stimated Cytochrome P 450 A ctivity b y U rinary M etabolite o f Exogenous C ortisol

  2000cites this paper
• Effects of obesity on pharmacokinetics implications for drug therapy.

  2000cites this paper
• Effects of Obesity on Pharmacokinetics

  2000cites this paper
• Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes.

  2000cites this paper
• Pharmacokinetic considerations in obesity.

  1999cites this paper
• In vivo comparison of putative probes of CYP3A4/5 activity: erythromycin, dextromethorphan, and verapamil

  1999cites this paper
• Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A

  1999cites this paper
• Cytochrome P450 3A

  1999cites this paper
• Effects of ketoconazole on the erythromycin breath test and the dapsone recovery ratio.

  1999cites this paper
• Effects of obesity on the cytochrome P450 enzyme system.

  1999cites this paper
• Differences in the Urinary Excretion of 6‐β‐Hydroxycortisol/Cortisol between Asian and Caucasian Women

  1999cites this paper
• CYP3A4 drug interactions: correlation of 10 in vitro probe substrates.

  1999cites this paper
• In vitro and in vivo drug interactions involving human CYP3A.

  1998cites this paper
• IN VITRO AND IN VIVO DRUG INTERACTIONS INVOLVING HUMAN CYP 3 A

  1998cites this paper
• Effects of interferon-alpha on cytochrome P-450 isoforms 1A2 and 3A activities in patients with chronic hepatitis C.

  1998cites this paper
• Neither dapsone hydroxylation nor cortisol 6β-hydroxylation detects the inhibition of CYP3A4 by HIV-1 protease inhibitors

  1998cites this paper
• Effect of Multiple Doses of Rifampin on the [14C N‐methyl] Erythromycin Breath Test in Healthy Male Volunteers

  1998cites this paper
• Human cytochrome P450s: selectivity and measurement in vivo.

  1998cites this paper